Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 770 • 2014 ACR/ARHP Annual Meeting
Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays
Frank Schneider¹ and Carol A. Feghali-Bostwick², ¹Pathology, University of Pittsburgh, Pittsburghh, PA, ²Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Research on systemic sclerosis (SSc)-associated interstitial lung disease (ILD) has been hindered by the paucity of lung tissues, as SSc patients with lung involvement…
Abstract Number: 765 • 2014 ACR/ARHP Annual Meeting
Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc)
Pravitt Gourh¹, Yoonhee Kim², Sandeep K. Agarwal³, Filemon K. Tan⁴, Shervin Assassi⁴, Javier Martin⁵, Frank C. Arnett⁴ and Maureen D Mayes⁴, ¹NIAMS-Rheumatology, National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁵Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose Systemic sclerosis (SSc) is a complex autoimmune disease and several genetic loci increasing SSc susceptibility have been identified with small to modest effect sizes.…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Lee S. Shapiro^1,2,3, Lesley Ann Saketkoo⁴, Jessica F. Farrell^2,3,5 and Kim Fligelstone⁶, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Center, Saratoga Springs, NY, ³The Center for Rheumatology, Albany, NY, ⁴Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁶Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…
Abstract Number: 2699 • 2014 ACR/ARHP Annual Meeting
Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Veronika K. Jaeger¹, Andrew Aubin², Nancy Baldwin³, Kim Fligelstone⁴, Robyn Sims⁵, Joep Welling⁶, Ryan Burrill⁷, Kerri Connolly⁷, Tracy Frech⁸, Jessica K. Gordon⁹, Tanaka Ngcozana¹⁰, Monika Kowalczyk¹¹, Matthew R. Lammi¹², Ulrich A. Walker¹ and Lesley Ann Saketkoo¹³, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Louisiana State University School of Medicine, New Orleans, LA, ³Scleroderma Foundation - Chicago Support Group, Chicago, IL, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Scleroderma Australia, Victoria, Australia, ⁶The Dutch Patient Organization for Systemic Autoimmune Diseases, Utrecht, Netherlands, ⁷Scleroderma Foundation, Boston, MA, ⁸Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ¹¹DIvision of Gastroenterology, Tulane University School of Medicine, New Orleans, LA, ¹²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ¹³Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on…
Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…
Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron¹, John T. Granton², Peter Lee³, John Thenganatt⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Christopher Pasarikovski¹, John T. Granton², Peter Lee³, Adrienne M. Roos¹, Amie T. Kron¹, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Hebah Alhajeri¹, Marie Hudson², Marvin J. Fritzler³, Janet E. Pope⁴, Canadian Scleroderma Research Group -⁵ and Murray Baron⁶, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴St Joseph Health Care, London, ON, Canada, ⁵Jewish General Hospital, Montreal, QC, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Aaliya Yaqub¹, Lorinda Chung², David Fiorentino³ and Eswar Krishnan⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…
Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Svetlana I. Nihtyanova¹, Benjamin E. Schreiber², Voon H. Ong³, John G. Coghlan⁴, Athol U. Wells⁵ and Christopher P. Denton⁶, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ³Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁴National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Elana J. Bernstein¹, Jessica K. Gordon², Wei-Ti Huang³ and Virginia D. Steen⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].